METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Clinical trials for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HORMONE-SENSITIVE PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise in slowing prostate cancer in chinese men
Disease control OngoingThis study tested whether adding enzalutamide to standard hormone therapy (ADT) helps Chinese men with prostate cancer that has spread but still responds to hormones. 180 participants received either enzalutamide plus ADT or a placebo plus ADT. The goal was to see if the combinat…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Astellas Pharma China, Inc. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New study tracks how well darolutamide works for advanced prostate cancer in everyday practice
Disease control OngoingThis study looks at how well the drug darolutamide (combined with hormone therapy, and sometimes chemotherapy) works for men whose prostate cancer has spread and still responds to hormones. About 1,600 men from Europe will be followed during their normal treatment. The goal is to…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Sponsor: Bayer • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New combo therapy aims to slow prostate cancer spread
Disease control OngoingThis study tests whether adding darolutamide to standard hormone therapy (ADT) can delay cancer worsening in men with metastatic hormone-sensitive prostate cancer. About 223 men will receive darolutamide plus ADT, and their results will be compared to a similar group that got ADT…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated May 08, 2026 12:01 UTC
-
Prostate cancer study seeks best combo therapy in real life
Knowledge-focused OngoingThis study looks at how well two different drug combinations work for men with advanced prostate cancer that has spread but still responds to hormone therapy. Researchers will track over 500 patients to compare the effects of apalutamide versus enzalutamide, both taken with stand…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Sponsor: Janssen-Cilag Ltd. • Aim: Knowledge-focused
Last updated May 17, 2026 03:12 UTC
-
Canadian prostate cancer study tracks Real-World treatment choices
Knowledge-focused OngoingThis study collects data from medical records of 700 Canadian men with metastatic hormone-sensitive prostate cancer to see how doctors actually intensify treatment over time. No new treatments or advice are given—researchers simply observe what happens in routine care. The goal i…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Sponsor: Bayer • Aim: Knowledge-focused
Last updated May 12, 2026 13:43 UTC